Final results of the TALENT trial (GETNE1509): a prospective multicohort phase II study of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs)
Authors
Capdevila, JFazio, N
Lopez, CL
Teule, A
Valle, Juan W
Tafuto, S
Custodio, AB
Reed, N
Raderer, M
Grande, E
Garcia-Carbonero, R
Jimenez-Fonseca, P
Alonso, V
Antonuzzo, L
Spallanzani, A
Berruti, A
Sevilla, I
Munoa, AL
Hernando-Cubero, J
Ibrahim, T
Affiliation
Medical Oncology Department, Vall d�Hebron University Hospital; Vall d�Hebron Institute of Oncology (VHIO), Barcelona, SpainIssue Date
2019
Metadata
Show full item recordCitation
Capdevila J, Fazio N, Lopez Lopez C, Teule A, Valle JW, Tafuto S, et al. Final results of the TALENT trial (GETNE1509): a prospective multicohort phase II study of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs). J Clin Oncol. 2019;37(15_suppl):4106-.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2019.37.15_suppl.4106Additional Links
https://dx.doi.org/10.1200/JCO.2019.37.15_suppl.4106Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2019.37.15_suppl.4106